1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Oncology Biosimilars Market
2.2. Global Oncology Biosimilars Market, By Drug Class, 2023 (US$ Million)
2.3. Global Oncology Biosimilars Market, By Disease Condition, 2023 (US$ Million)
2.4. Global Oncology Biosimilars Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Oncology Biosimilars Market: Competitive Analysis
3.1. Market Positioning of Key Oncology Biosimilars Market Vendors
3.2. Strategies Adopted by Oncology Biosimilars Market Vendors
3.3. Key Industry Strategies
4. Oncology Biosimilars Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Oncology Biosimilars Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Monoclonal Antibodies
5.3.2. Granulocyte Colony-Stimulating Factor (G-CSF)
5.3.3. Pipeline Analysis
5.3.3.1. Phase III Drug Analysis
5.3.3.1.1. Rituximab Biosimilar
5.3.3.1.2. Trastuzumab Biosimilar
5.3.3.1.3. Filgrastim Biosimilar
5.3.3.1.4. Bevacizumab Biosimilar
5.3.3.2. Tabular Representation of Phase I and Phase II Drugs

6. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Breast Cancer
6.3.2. Lung Cancer
6.3.3. Colorectal Cancer
6.3.4. Cervical Cancer
6.3.5. Blood Cancer
6.3.6. Neutropenia
6.3.7. Others (Brain Cancer, Stomach Cancer, etc.)


7. North America Oncology Biosimilars Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
7.3. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
7.4.Oncology Biosimilars Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.1.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.2.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.3.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)

8. UK and European Union Oncology Biosimilars Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
8.3. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
8.4.Oncology Biosimilars Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.1.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.2.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.3.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.4.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.5.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.6.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)

9. Asia Pacific Oncology Biosimilars Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
9.3. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
9.4.Oncology Biosimilars Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.1.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.2.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.3.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.4.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.5.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.6.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)

10. Latin America Oncology Biosimilars Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
10.3. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
10.4.Oncology Biosimilars Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.1.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.2.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.3.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)

11. Middle East and Africa Oncology Biosimilars Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
11.3. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
11.4.Oncology Biosimilars Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.1.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.2.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Oncology Biosimilars Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.3.2. Oncology Biosimilars Market: By Disease Condition, 2022-2032, USD (Million)

12. Company Profile
12.1. Amgen, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Mylan N.V.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Samsung Bioepis Co. Ltd.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Teva Pharmaceutical Industries Ltd.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Pfizer, Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Celltrion Healthcare
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Novartis International AG
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Biocon Limited
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Biogen Idec
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Sandoz
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Dr. Reddy’s Laboratory
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Merck & Co.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
12.13. Shanghai Henlius Biotech, Inc.
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Portfolio
12.13.4. Strategic Initiatives
12.14. Biocad
12.14.1. Company Overview
12.14.2. Financial Performance
12.14.3. Product Portfolio
12.14.4. Strategic Initiatives